诺华去铁药地拉罗司怎么购买？

(Deferasirox) is an iron chelator product developed by Novartis Pharma Schweiz AG in Switzerland. It has a long half-life, is convenient for oral administration, and has iron-removing effects similar to DFO and lower adverse reactions. Related foreign treatment guidelines have designated deferasirox as the first-line iron-removing drug for thalassemia. Domestic studies have reported that this drug can significantly reduce the level of serum ferritin in patients.

In 2005, deferasirox was approved by the FDA to be officially marketed in the United States; in 2010, deferasirox dispersible tablets were approved for marketing in China and were approved for the treatment of chronic iron overload caused by frequent blood transfusions in patients with β-thalassemia aged 2 years and older and for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above. The drug is currently available in more than 80 countries. In these listed countries and regions, patients can purchase the Novartis iron-deficient drug deferasirox they need. If you need to purchase medicines overseas, patients can also contact Medical Companion Travel to obtain the purchase channels for the required medicines.

Swiss Novartis AG is a leading multinational company in the global pharmaceutical and consumer health care industries and one of the world's three largest pharmaceutical companies. It operates in more than 150 countries and regions around the world and has 138,000 employees. The Swiss company Novartis has a diversified product portfolio, all of which are in a leading position in the world. Its Deferasirox has received widespread attention once it was launched.

The 2019 Novartis financial report shows that the global sales of deferasirox in 2019 reached US$975 million; domestic deferasirox dispersible tablets entered the latest version of the medical insurance catalog through national negotiations in 2019; public data shows that domestic sales in the first three quarters of 2019 were: 7.0029 million US dollars.

Recommended hot articles: /newsDetail/92219.html